 |
 |
New Client Alert! PT: CNSX is Ready to Roll
Pacific Therapeutics Ltd.
1023 - 409 Granville Street
Vancouver British Columbia
V6C 1T2
Phone: 1-604-738-1049
Fax: 1-604-738-1094
pacifictherapeutics.com
PROFILE:
The company's strategy includes the reformulation and repurposing of FDA approved drugs to treat excessive scarring in liver and lung disease. Pacific Therapeutics will complete clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing and sales authorizations of its drug candidates in the US, Europe, Canada and other countries.
Pacific Therapeutics' lead drug candidate; PTL-202 is has recently completed a Phase 1 clinical. PTL-202 is a combination of drugs that have been approved by the FDA to treat diseases other than fibrosis. PTL-202 is being developed by Pacific Therapeutics to treat a progressive lung scarring disease, named Idiopathic Pulmonary Fibrosis (IPF). More people die annually of IPF than either prostate or breast cancer. IPF is estimated to be a 2 billion dollar market opportunity.
On August 21, 2012 Pacific Therapeutics initiated its phase 1 clinical trial. CRBIO (Clinical Research and Biosciences of Hyderabad), India conduct the clinical trial with PTL-202 in a drug to drug interaction study in humans.
Pacific Therapeutics' second drug candidate, PTL-303, is also a combination of drugs, one of which has been approved for human use in Japan. PTL-303 has been shown to be effective in the reduction of molecules that contribute to the development of diseases including, liver cirrhosis in humans. PTL-303 may be developed as a treatment to reduce the severity of progressive diseases like chronic liver disease.
Chronic liver disease which may lead to cirrhosis of the liver is responsible for over 1.4m deaths annually (WHO, World Health Report 2004) In the US chronic liver disease is among the top ten disease related causes of death (CDC, National Center for Health Statistics, 2004). This market is estimated to be $3.0 billion.
A provisional patent covering PTL-202 titled: "Composition and Method for Treating Fibrosis" was filed by the company with the United States patent office on October 29, 2008. A PCT application covering the technology of PTL-303 was filed October, 2009. Both patent applications have now entered the national phase.
Pacific Therapeutics' business and drug development strategy reduces risk, time and the capital costs of developing new drug therapies for liver and lung diseases caused by fibrosis. By combining existing approved drugs that have already known safety and toxicity profiles, the company eliminates the inherent risks involved with basic pre clinical research and animal testing.
VALUE PROPOSITION:
Lower Development Expense. Whereas it costs typical biotechnology companies hundreds of millions to develop new drugs, Pacific Therapeutics Ltd. is utilizing FDA-approved drugs in new formulations to save time and money.
Unique Lead Drug Candidate. Pacific's flagship drug candidate, PTL-202 is a patent-pending cocktail using Pentoxifylline and N-Acetyl-Cysteine, two FDA-approved drugs that have proven therapeutic benefits as a pan-phosphodiesterase inhibitor and a potent antioxidant.
Massive Market. Idiopathic Pulmonary Fibrosis represents a 2 billion dollar market opportunity with more than 5 million patients globally suffering from the condition and a death rate that is higher than either breast or prostate cancer. Once diagnosed, IPF patients typically do not live past five years with most patients dying of respiratory failure. No approved treatments are available currently.
Clinical Trials. PTL-202 is currently in the midst of a clinical trial in India testing its safety and tolerability in healthy patients under the guidance of a leading CRO. The data will be used to advance PTL-202 into larger, later-stage trials.
More in the Pipeline. Pacific's PTL-303 is a combination of drugs that have been approved for use in Japan. This combination has a wide range of uses including, treating, preventing and reducing disorders of progressive scarring in humans. Chronic liver disease kills more than 1.4 million people globally each year and is estimated to be 3.0 billion dollar market opportunity with no approved therapies today.
Solid Capital Structure. Pacific's share structure is in order and, for a biotechnology company with a drug candidate in clinical trials, exceptionally small with only 28,220,081 shares (fully diluted). The company has cash on hand thanks in part to two tranches of a non-brokered private placement that has totaled gross proceeds of $229,650. |
|
CNSX: PT
Issued and Outstanding:
23,376,161
Reserved for Issuance:
4,653,000
Transfer Agent:
Valiant Trust
RECENT NEWS:
Pacific Therapeutics Ltd. Announces Issuance of Convertible Note
Pacific Therapeutics Ltd. Announces Closing of Second Tranche of Non-Brokered Private Placement and Investor Relations Contract
KEY EXECUTIVES:
Douglas H. Unwin
President
Chief Executive Officer
Director
Derick Sinclair
Chief Financial Officer
|
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
